RPL17 and neoplasm: To investigate whether local activation of NLRP3 could drive systemic antitumor immunity, resulting in abscopal antitumor effects, BMS-986299 (intratumorally 6 to 100 μg Q2D×3 or Q1W) ± anti-PD-1 or anti-CTLA-4 CPI (intraperitoneally) was evaluated in mouse syngeneic tumor models (eg, EG7 thymoma and MC38 colon adenocarcinoma); abscopal activity was measured in a noninjected distal tumor.